# The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

> **NCT05203172** · PHASE4 · RECRUITING · sponsor: **Pfizer** · enrollment: 46 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Binimetinib only treatment
- **DRUG:** Encorafenib only Treatment
- **DRUG:** Encorafenib & Binimetinib Treatment
- **DRUG:** Treatment of Encorafenib & Binimetinib & Ribociclib
- **DRUG:** Treatment of Encorafenib & Binimetinib & Cetuximab

## Key facts

- **NCT ID:** NCT05203172
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-05
- **Primary completion:** 2029-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05203172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05203172, "The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05203172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*